75 related articles for article (PubMed ID: 18080979)
1. [Cytokeratins - tissue and biochemical markers of non-small cell lung cancer].
Szturmowicz M
Pneumonol Alergol Pol; 2007; 75(4):315-6. PubMed ID: 18080979
[No Abstract] [Full Text] [Related]
2. [Level of cytokeratin-19 in serum of patients with non small cell lung cancer].
Cynowska B; Słomiński JM; Wyrwiński J
Pneumonol Alergol Pol; 1995; 63(11-12):615-20. PubMed ID: 8616476
[TBL] [Abstract][Full Text] [Related]
3. Prognostic markers for stage I non-small cell lung cancer.
Mizuguchi S; Nishiyama N
Lung Cancer; 2008 Feb; 59(2):274-5. PubMed ID: 18055061
[No Abstract] [Full Text] [Related]
4. Invited commentary.
D'Amico T
Ann Thorac Surg; 2007 Jan; 83(1):221-2. PubMed ID: 17184667
[No Abstract] [Full Text] [Related]
5. [Value of tumor markers in monitoring of cytotoxic treatment of non-small cell lung cancer].
Załeska M
Pneumonol Alergol Pol; 2003; 71(7-8):359-64. PubMed ID: 15052970
[No Abstract] [Full Text] [Related]
6. [Clinical usefulness of serum assay of EIA-CYFRA 21-1 in lung cancer].
Satoh H; Yagyu H; Sumi M; Ishikawa H; Hamada M; Suyama T; Naitoh T; Inoue M; Saitoh T; Uchida Y
Gan To Kagaku Ryoho; 1994 May; 21(6):795-9. PubMed ID: 7514388
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Cyfra 21-1 as a marker for lung cancer.
Najemnik C; Mohn-Staudner A; Vetter H; Kokron O; Baumgartner G; Scheiner W; Zwick H; Koderhold G; Alth G; Dudczak R
Wien Klin Wochenschr; 1996; 108(15):467-72. PubMed ID: 8806188
[TBL] [Abstract][Full Text] [Related]
8. [Cyfra 21-1--a new tumor marker of the cytokeratin series in differential diagnosis of lung diseases].
Oremek GM; Seiffert UB; Siekmeier R; Kirsten R
Med Klin (Munich); 1995 Jan; 90(1):23-6. PubMed ID: 7533887
[TBL] [Abstract][Full Text] [Related]
9. [Clinical value of combined detection of serum tumor markers in lung cancer diagnosis].
Chen F; Li WM; Wang DM; Gao SS; Bao Y; Chen WB; Liu D
Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Sep; 39(5):832-5. PubMed ID: 19024326
[TBL] [Abstract][Full Text] [Related]
10. Utility of serum cytokeratin 19 fragment (CYFRA 21-1) and carcinoembryonic antigen (CEA) as tumour markers for non-small cell lung cancer.
Chantapet P; Riantawan P; Lebnak P; Getngern P
J Med Assoc Thai; 2000 Apr; 83(4):383-91. PubMed ID: 10808698
[TBL] [Abstract][Full Text] [Related]
11. Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer.
Tas F; Aydiner A; Topuz E; Yasasever V; Karadeniz A; Saip P
J Exp Clin Cancer Res; 2000 Dec; 19(4):477-81. PubMed ID: 11277326
[TBL] [Abstract][Full Text] [Related]
12. Erythrocyte and platelet phospholipid fatty acids as markers of advanced non-small cell lung cancer: comparison with serum levels of sialic acid, TPS and Cyfra 21-1.
de Castro J; Rodríguez MC; Martínez-Zorzano VS; Hernández-Hernández A; Llanillo M; Sánchez-Yagüe J
Cancer Invest; 2008 May; 26(4):407-18. PubMed ID: 18443962
[TBL] [Abstract][Full Text] [Related]
13. Value of tumour and inflammatory markers in lung cancer.
Oremek GM; Sauer-Eppel H; Bruzdziak TH
Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
[TBL] [Abstract][Full Text] [Related]
14. Arterial carboxyhemoglobin concentrations in elderly patients with operable non-small cell lung cancer.
Yasuda H; Yamaya M; Ebihara S; Sasaki T; Inoue D; Kubo H; Sasaki H; Suzuki S
J Am Geriatr Soc; 2004 Sep; 52(9):1592-3. PubMed ID: 15341582
[No Abstract] [Full Text] [Related]
15. Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer.
Matsuoka K; Sumitomo S; Nakashima N; Nakajima D; Misaki N
Eur J Cardiothorac Surg; 2007 Sep; 32(3):435-9. PubMed ID: 17611117
[TBL] [Abstract][Full Text] [Related]
16. [Biological markers in lung cancer].
Nikliński J; Furman M
Pneumonol Alergol Pol; 1991; 59(5-6):253-9. PubMed ID: 1668877
[No Abstract] [Full Text] [Related]
17. [The significance of the serum tumour markers as a prognostic and predictor factors in nonsmall cell lung cancer patients].
Załeska M; Szturmowicz M; Zych J; Remiszewski P; Płodziszewskal M; Szopiński J; Załeska J; Demkow U; Langfort R; Roszkowska-Sliz B; Roszkowski-Sliz K
Pneumonol Alergol Pol; 2005; 73(3):270-6. PubMed ID: 16989165
[TBL] [Abstract][Full Text] [Related]
18. Reproducibility of a semiquantitative measurement of circulating DNA in plasma from neoplastic patients.
Frattini M; Balestra D; Verderio P; Gallino G; Leo E; Sozzi G; Pierotti MA; Daidone MG
J Clin Oncol; 2005 May; 23(13):3163-4; author reply 3164-5. PubMed ID: 15860889
[No Abstract] [Full Text] [Related]
19. Tumor volume and tumor marker index based on CYFRA 21-1 and CEA are strong prognostic factors in operated early stage NSCLC.
Muley T; Fetz TH; Dienemann H; Hoffmann H; Herth FJ; Meister M; Ebert W
Lung Cancer; 2008 Jun; 60(3):408-15. PubMed ID: 18083270
[TBL] [Abstract][Full Text] [Related]
20. Clinical value of serum cytokeratin 19 fragment and sialyl-Lewis x in non-small cell lung cancer.
Mizuguchi S; Nishiyama N; Iwata T; Nishida T; Izumi N; Tsukioka T; Inoue K; Kameyama M; Suehiro S
Ann Thorac Surg; 2007 Jan; 83(1):216-21. PubMed ID: 17184666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]